Navigation Links
NX Prenatal Appoints Leading Experts to Medical/Clinical Advisory Board
Date:1/19/2017

LOUISVILLE, Ky. and HOUSTON, Jan. 19, 2017 /PRNewswire/ -- NX Prenatal Inc. ("NX Prenatal") today announced the formation of its Medical/Clinical Advisory Board.  This new board brings together leading clinicians and industry veterans who enhance the range and depth of expertise of the company as it accelerates development of its novel prenatal diagnostic tests.  These experts are uniquely positioned to provide medical, clinical and strategic guidance for the company's product development and commercialization activities. The first product will be a novel exosome-based blood test designed to stratify the risk of preterm birth in women as early as 10-12 weeks of pregnancy to provide physicians with a new decision support tool.

Gail Page, NX Prenatal's Executive Chairperson, added, "We are pleased to be surrounded by advisors who have deep knowledge in the fields of maternal fetal medicine, obstetrics, proteomics, and biomarker test commercialization.  We recognize the importance of working closely with key opinion leaders to ensure that our diagnostic tests are relevant and address an unmet need in the clinical community that will use them."

Continue Reading
It is estimated that more than over half of women who deliver prematurely have no traditional risk factors. There is a clear need for new blood tests that can provide early identification of at-risk patients, allowing adequate time to implement intensified care protocols.
It is estimated that more than over half of women who deliver prematurely have no traditional risk factors. There is a clear need for new blood tests that can provide early identification of at-risk patients, allowing adequate time to implement intensified care protocols.

The advisory board members include:

Kevin Rosenblatt, MD, PhD (Chair)
Dr. Rosenblatt is Chief Medical & Scientific Officer of NX Prenatal.  He previously served as CMO/CSO of CompanionDx Labs, a precision medicine/diagnostics company. Dr. Rosenblatt is recognized internationally for his proteomics and genomics expertise and has published over 60 papers on biomarker development and clinical proteomics. He served as an Associate Professor in the Division of Oncology, Department of Internal Medicine, Associate Professor at the Brown Foundation Institute of Molecular Medicine and as Director of the Proteomics Core for the Center for Clinical and Translational Sciences at UT Health.  He also previously served as CSO and Laboratory Director of Risk Assessment Laboratories, LLC, which focused on the development of preterm birth biomarkers. 

Mary Lake Polan, MD, PhD, MPH
Dr. Polan is a Clinical Professor in the Department of Obstetrics and Gynecology and Reproductive Sciences Yale University School of Medicine; she is also Chair Emeritus of the Department of Obstetrics and Gynecology at Stanford University.  She has published more than 130 articles, chapters, and books in her areas of research, which include reproductive endocrinology and infertility.  She is a member of the National Academy of Medicine and has served on a number of NIH and university committees.

Daniel W. Chan, PhD, DABCC, FACB
Dr. Chan is Professor of Pathology, Oncology, Radiology, and Urology at the Johns Hopkins University School of Medicine, and Director of the Clinical Chemistry Division and Co-Director of the Pathology Core Laboratory of Johns Hopkins Hospital in Baltimore.  Dr. Chan is also Director of the Biomarker Discovery and Translation Center, Johns Hopkins University. Dr. Chan received his BA degree in Biology from the University of Oregon and his Ph.D. in Biochemistry from the State University of New York at Buffalo.  He is an internationally recognized expert in cancer biomarkers, clinical proteomics and molecular diagnostics.  He has written 5 books, 40 book chapters and 300 scientific articles.   He is the Editor-in-Chief of the journal Clinical Proteomics.

Thomas McElrath, MD, PhD, FACOG
Dr. McElrath is Associate Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School and an attending physician at Brigham & Women's Hospital where he specializes in Maternal & Fetal Medicine with a focus on the prevention of spontaneous preterm birth.  Dr. McElrath manages the Preterm Birth Clinic at Brigham and Women's Hospital.  He actively publishes on the biomarker epidemiology and classification of preterm birth and the interaction of environmental conditions and exposures with the risk of preterm birth.

About NX Prenatal
NX Prenatal Inc. is a private, US-based molecular diagnostics company.  The company's NeXosome® Preterm Birth Risk Assay is positioned to be an enabling, early warning system for pregnancies that may result in spontaneous preterm birth.   Using its proprietary NeXosome Platform, NX Prenatal has demonstrated the potential utility of a new library of biomarkers for prenatal risk assessment as early as 10 weeks gestation.  This technology exploits biologically active and stable microparticles, such as exosomes, from the maternal bloodstream, to provide a real-time and non-invasive view of changing maternal and fetal cells and tissues. 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nx-prenatal-appoints-leading-experts-to-medicalclinical-advisory-board-300393667.html


'/>"/>
SOURCE NX Prenatal Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. NxGen MDx announces the move of their Non-invasive Prenatal Test in-house
2. New NX Prenatal Preterm Birth Risk Biomarker Data Presented at Society for Maternal Fetal Medicine Annual Meeting
3. Global Non-Invasive Prenatal Testing Market: Rising Average Maternal Age Worldwide to Fuel Market at 17.50% CAGR: Transparency Market Research
4. ArmaGen Appoints Mathias Schmidt, Ph.D., as Chief Executive Officer
5. uBiome Appoints Boston Children’s Hospital Genomics Expert, Dr. Olaf Bodamer, to its Advisory Board
6. UAS Labs Appoints Ronald Pillsbury as Chief Operating Officer
7. Department of Health and Human Services Appoints Dr. Stephen Rosenfeld SACHRP Chair
8. Anaconda BioMed S.L. Appoints Dr. Tudor Jovin to its Scientific Advisory Board (SAB)
9. Vyriad Appoints Alvin E. McQuinn to Board of Directors
10. Muse bio appoints proven biotech industry executive and innovator, Kevin Ness, as CEO
11. ACEA Biosciences Appoints Li Xu, M.D. as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):